Press "Enter" to skip to content

AstraZeneca-Daiichi Sankyo breast cancer drug shows promise

The treatment Trastuzumab Deruxtecan, or DS-8201, demonstrated a clinically meaningful response in patients with refractory HER2-positive metastatic breast cancer, the two companies said in a joint statement.

Original source: https://health.economictimes.indiatimes.com/news/pharma/astrazeneca-daiichi-sankyo-breast-cancer-drug-shows-promise/69244271?utm_source=RSS&utm_medium=ETRSS

Also Read:   Amgen takes 20.5% stake in BeiGene to sell cancer drugs in China